Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things: Pfizer to boost migraine presence via M&A; Roche’s immunotherapy ambitions take a hit; Biogen’s CEO search gets more complicated; Stoffels lays out new strategy for Galapagos; and mixed results for Japanese majors.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 13 May 2022, including: Pfizer Inc. to boost migraine presence via M&A; Roche Holding AG’s immunotherapy ambitions take a hit; Biogen, Inc.’s CEO search gets more complicated; Stoffels lays out new strategy for Galapagos NV; and mixed results for Japanese majors.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Pfizer To Put Big Marketing Muscle Behind Migraine With Biohaven Purchase" - Scrip, 10 May, 2022.)
(Also see "Blow To Roche Growth Prospects As TIGIT Lung Cancer Trial Fails" - Scrip, 11 May, 2022.)
(Also see "Lecanemab Filing Complicates Biogen's Hunt For New CEO" - Scrip, 11 May, 2022.)
(Also see "Stoffels Sets Out Strategy To Save Galapagos" - Scrip, 9 May, 2022.)
(Also see "Mainstays Give And Take As Major Japan Firms Report Results" - Scrip, 11 May, 2022.)